| East Mountain Hospice, Llc 12126 N Hwy 14, Cedar Crest, NM, 87008 | |
| (505) 286-4219 |
News Archive
A team of researchers at Columbia University and the New York City Department of Health and Mental Hygiene have shown that this move by the government was effective in reducing the spread of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes the coronavirus disease (COVID-19).
The Miriam Hospital is actively recruiting local participants for a U.S. clinical trial of the Parachute device for treating heart failure. The study is focused on determining if the new minimally invasive catheter-based device can slow the progression of heart failure, reduce repeat hospitalizations and death, and significantly improve quality of life for patients who experience enlargement of the left ventricle after a heart attack.
Agilent Technologies Inc. and SeqWright DNA Technology Services today announced that SeqWright is the first Certified Service Provider for the Agilent SureSelect Target Enrichment System for use with the next-generation AB SOLiD sequencing platform.
ARYx Therapeutics, Inc., a biopharmaceutical company, announced that a review of the results of the Phase 2b clinical trial, PASCAL, testing the efficacy and safety of ARYx's compound for the treatment of atrial fibrillation, budiodarone, was presented today at the American Heart Association meeting in Orlando, Florida.
› Verified 9 days ago
| Name | East Mountain Hospice, Llc |
|---|---|
| Location | 12126 N Hwy 14, Cedar Crest, New Mexico |
| Hospice ID | 321573 |
| Category | Freestanding Hospice |
| Ownership Type | Other |
| Profit Type | OTHER |
| Accreditation Provider | Community Health Accreditation Partner (CHAP) |
| SSA county code | 000 |
News Archive
A team of researchers at Columbia University and the New York City Department of Health and Mental Hygiene have shown that this move by the government was effective in reducing the spread of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes the coronavirus disease (COVID-19).
The Miriam Hospital is actively recruiting local participants for a U.S. clinical trial of the Parachute device for treating heart failure. The study is focused on determining if the new minimally invasive catheter-based device can slow the progression of heart failure, reduce repeat hospitalizations and death, and significantly improve quality of life for patients who experience enlargement of the left ventricle after a heart attack.
Agilent Technologies Inc. and SeqWright DNA Technology Services today announced that SeqWright is the first Certified Service Provider for the Agilent SureSelect Target Enrichment System for use with the next-generation AB SOLiD sequencing platform.
ARYx Therapeutics, Inc., a biopharmaceutical company, announced that a review of the results of the Phase 2b clinical trial, PASCAL, testing the efficacy and safety of ARYx's compound for the treatment of atrial fibrillation, budiodarone, was presented today at the American Heart Association meeting in Orlando, Florida.
› Verified 9 days ago
| NPI Number | 1548633563 |
| Organization Name | East Mountain Hospice Llc |
| Address | 12126 Hwy 14 N Ste A Cedar Crest, New Mexico, 87008 |
| Phone Number | (505)286-4219 |
News Archive
A team of researchers at Columbia University and the New York City Department of Health and Mental Hygiene have shown that this move by the government was effective in reducing the spread of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes the coronavirus disease (COVID-19).
The Miriam Hospital is actively recruiting local participants for a U.S. clinical trial of the Parachute device for treating heart failure. The study is focused on determining if the new minimally invasive catheter-based device can slow the progression of heart failure, reduce repeat hospitalizations and death, and significantly improve quality of life for patients who experience enlargement of the left ventricle after a heart attack.
Agilent Technologies Inc. and SeqWright DNA Technology Services today announced that SeqWright is the first Certified Service Provider for the Agilent SureSelect Target Enrichment System for use with the next-generation AB SOLiD sequencing platform.
ARYx Therapeutics, Inc., a biopharmaceutical company, announced that a review of the results of the Phase 2b clinical trial, PASCAL, testing the efficacy and safety of ARYx's compound for the treatment of atrial fibrillation, budiodarone, was presented today at the American Heart Association meeting in Orlando, Florida.
› Verified 9 days ago
| Quality Measure | Provider Score | National Score |
|---|---|---|
| Patients or caregivers who were asked about treatment preferences like hospitalization and resuscitation at the beginning of hospice care | Not Available | 98.3 |
| Patients or caregivers who were asked about their beliefs and values at the beginning of hospice care | Not Available | 93.6 |
| Patients who were checked for pain at the beginning of hospice care | Not Available | 93.9 |
| Patients who got a timely and thorough pain assessment when pain was identified as a problem | Not Available | 77.7 |
| Patients who were checked for shortness of breath at the beginning of hospice care | Not Available | 97.3 |
| Patients who got timely treatment for shortness of breath | Not Available | 94.6 |
| Patients taking opioid pain medication who were offered care for constipation | Not Available | 93.3 |
News Archive
A team of researchers at Columbia University and the New York City Department of Health and Mental Hygiene have shown that this move by the government was effective in reducing the spread of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes the coronavirus disease (COVID-19).
The Miriam Hospital is actively recruiting local participants for a U.S. clinical trial of the Parachute device for treating heart failure. The study is focused on determining if the new minimally invasive catheter-based device can slow the progression of heart failure, reduce repeat hospitalizations and death, and significantly improve quality of life for patients who experience enlargement of the left ventricle after a heart attack.
Agilent Technologies Inc. and SeqWright DNA Technology Services today announced that SeqWright is the first Certified Service Provider for the Agilent SureSelect Target Enrichment System for use with the next-generation AB SOLiD sequencing platform.
ARYx Therapeutics, Inc., a biopharmaceutical company, announced that a review of the results of the Phase 2b clinical trial, PASCAL, testing the efficacy and safety of ARYx's compound for the treatment of atrial fibrillation, budiodarone, was presented today at the American Heart Association meeting in Orlando, Florida.
› Verified 9 days ago
| Home Health Aides | 2 |
| Counselors | 1 |
| Medical Social Workers | 1 |
| Registered Nurses | 1 |
| Other Personnel | 1 |
| Total Employees | 6 |
|---|
News Archive
A team of researchers at Columbia University and the New York City Department of Health and Mental Hygiene have shown that this move by the government was effective in reducing the spread of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes the coronavirus disease (COVID-19).
The Miriam Hospital is actively recruiting local participants for a U.S. clinical trial of the Parachute device for treating heart failure. The study is focused on determining if the new minimally invasive catheter-based device can slow the progression of heart failure, reduce repeat hospitalizations and death, and significantly improve quality of life for patients who experience enlargement of the left ventricle after a heart attack.
Agilent Technologies Inc. and SeqWright DNA Technology Services today announced that SeqWright is the first Certified Service Provider for the Agilent SureSelect Target Enrichment System for use with the next-generation AB SOLiD sequencing platform.
ARYx Therapeutics, Inc., a biopharmaceutical company, announced that a review of the results of the Phase 2b clinical trial, PASCAL, testing the efficacy and safety of ARYx's compound for the treatment of atrial fibrillation, budiodarone, was presented today at the American Heart Association meeting in Orlando, Florida.
› Verified 9 days ago
| Others | 1 |
| Total Volunteers | 1 |
|---|
News Archive
A team of researchers at Columbia University and the New York City Department of Health and Mental Hygiene have shown that this move by the government was effective in reducing the spread of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes the coronavirus disease (COVID-19).
The Miriam Hospital is actively recruiting local participants for a U.S. clinical trial of the Parachute device for treating heart failure. The study is focused on determining if the new minimally invasive catheter-based device can slow the progression of heart failure, reduce repeat hospitalizations and death, and significantly improve quality of life for patients who experience enlargement of the left ventricle after a heart attack.
Agilent Technologies Inc. and SeqWright DNA Technology Services today announced that SeqWright is the first Certified Service Provider for the Agilent SureSelect Target Enrichment System for use with the next-generation AB SOLiD sequencing platform.
ARYx Therapeutics, Inc., a biopharmaceutical company, announced that a review of the results of the Phase 2b clinical trial, PASCAL, testing the efficacy and safety of ARYx's compound for the treatment of atrial fibrillation, budiodarone, was presented today at the American Heart Association meeting in Orlando, Florida.
› Verified 9 days ago
| East Mountain Hospice, Llc Location: 12126 N Hwy 14, Cedar Crest, New Mexico, 87008 Phone: (505) 286-4219 |